Evaluation of a recombinant DNA hepatitis B vaccine in a vaccinated Nigerian population | Zendy

Moses P. Adoga | Zendy; G. R. I. Pennap | Zendy; Becky O. Akande | Zendy; Jamey P. Mairiga | Zendy; Simon Pechulano | Zendy; Simon M. Agwale | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of a recombinant DNA hepatitis B vaccine in a vaccinated Nigerian population

Author(s) -

Moses P. Adoga,

G. R. I. Pennap,

Becky O. Akande,

Jamey P. Mairiga,

Simon Pechulano,

Simon M. Agwale

Publication year - 2010

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.823

Subject(s) - medicine , hepatitis b vaccine , titer , immunogenicity , hepatitis b , vaccination , antibody , population , nigerians , immunology , antibody titer , virology , hepatitis b virus , virus , hbsag , political science , law , environmental health

Recombinant hepatitis B vaccine was introduced in 1986 and has gradually replaced the plasma-derived hepatitis B vaccine. No published data are available on the immunogenicity of hepatitis B vaccines in Nigerians. The current study aimed to evaluate protective sero-conversion rates after vaccination with Shanvac-B rDNA hepatitis B vaccine in Nigerian subjects between January and September 2009.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research